Lataa...
Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration
BACKGROUND: Monoclonal antibodies targeting vascular endothelial growth factor (VEGF), such as bevacizumab, are administered intravitreally for the treatment of wet or exudative age-related macular degeneration (ARMD). Systemic use of bevacizumab has been linked to a wide range of renal adverse effe...
Tallennettuna:
| Julkaisussa: | J Nephropathol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Society of Diabetic Nephropathy Prevention
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5607973/ https://ncbi.nlm.nih.gov/pubmed/28975092 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15171/jnp.2017.23 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|